PL370746A1 - Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma - Google Patents
Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthmaInfo
- Publication number
- PL370746A1 PL370746A1 PL02370746A PL37074602A PL370746A1 PL 370746 A1 PL370746 A1 PL 370746A1 PL 02370746 A PL02370746 A PL 02370746A PL 37074602 A PL37074602 A PL 37074602A PL 370746 A1 PL370746 A1 PL 370746A1
- Authority
- PL
- Poland
- Prior art keywords
- ccr
- asthma
- treatment
- receptor antagonists
- piperazine derivatives
- Prior art date
Links
- 102000004499 CCR3 Receptors Human genes 0.000 title 1
- 108010017316 CCR3 Receptors Proteins 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- 150000004885 piperazines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33465501P | 2001-11-30 | 2001-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL370746A1 true PL370746A1 (en) | 2005-05-30 |
Family
ID=23308174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02370746A PL370746A1 (en) | 2001-11-30 | 2002-11-25 | Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6906073B2 (https=) |
| EP (1) | EP1453514B1 (https=) |
| JP (1) | JP2005516903A (https=) |
| KR (1) | KR100586131B1 (https=) |
| CN (1) | CN1321115C (https=) |
| AR (1) | AR037459A1 (https=) |
| AT (1) | ATE367160T1 (https=) |
| AU (1) | AU2002352122A1 (https=) |
| BR (1) | BR0214582A (https=) |
| CA (1) | CA2467966A1 (https=) |
| DE (1) | DE60221275T2 (https=) |
| ES (1) | ES2290346T3 (https=) |
| MX (1) | MXPA04004981A (https=) |
| PL (1) | PL370746A1 (https=) |
| RU (1) | RU2004120063A (https=) |
| WO (1) | WO2003045393A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7262197B2 (en) * | 2003-03-31 | 2007-08-28 | Janssen Pharmaceutica, N.V | Phospholipase C inhibitors for use in treating inflammatory disorders |
| US20040235855A1 (en) * | 2003-03-31 | 2004-11-25 | Bharat Lagu | Phospholipase C inhibitors for use in treating inflammatory disorders |
| EP1640361B9 (en) * | 2003-06-30 | 2015-11-04 | Sumitomo Chemical Company, Limited | Asymmetric urea compounds and process for producing asymmetric compounds by asymmetric conjugate addition reaction using the same as catalyst |
| AU2005245401A1 (en) * | 2004-05-12 | 2005-12-01 | Chemocentryx | Aryl sulfonamides |
| WO2007005214A1 (en) * | 2005-06-29 | 2007-01-11 | Janssen Pharmaceutica, N.V. | Substituted {4(4-phenyl-piperazin-1yl)-cyclohexyl}-urea compounds |
| WO2007053436A1 (en) * | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| US8338426B2 (en) * | 2007-07-03 | 2012-12-25 | Janssen Pharmaceutica Nv | Piperazinyl derivatives useful as modulators of the neuropeptide Y2 receptor |
| WO2010025375A1 (en) * | 2008-08-29 | 2010-03-04 | Treventis Corporation | Compositions and methods of treating amyloid disease |
| RU2539591C2 (ru) * | 2009-04-22 | 2015-01-20 | Аксикин Фармасьютикалз, Инк. | Антагонисты арилсульфонамида ccr3 |
| MX2011011080A (es) * | 2009-04-22 | 2012-02-23 | Axikin Pharmaceuticals Inc | Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida. |
| JP7142675B2 (ja) * | 2017-03-26 | 2022-09-27 | 武田薬品工業株式会社 | Ｇｐｒ６のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド |
| EP3821947A1 (en) * | 2019-11-13 | 2021-05-19 | Libra Therapeutics, Inc. | Heterocyclic trpml1 agonists |
| TW202136219A (zh) * | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Trpml調節劑 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0592921A (ja) | 1991-05-17 | 1993-04-16 | Yamanouchi Pharmaceut Co Ltd | シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤 |
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| ATE293603T1 (de) * | 1997-10-14 | 2005-05-15 | Mitsubishi Pharma Corp | Piperazin-verbindungen und ihre medizinische verwendung |
| JP2002179651A (ja) * | 1998-06-19 | 2002-06-26 | Wakamoto Pharmaceut Co Ltd | ベンズアニリド誘導体及び医薬組成物 |
| US6486180B1 (en) | 1998-12-18 | 2002-11-26 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| DE69926806D1 (de) | 1998-12-18 | 2005-09-22 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
| WO2000035449A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| CA2350730A1 (en) | 1998-12-18 | 2000-06-22 | George V. Delucca | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6492400B1 (en) | 1998-12-18 | 2002-12-10 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
-
2002
- 2002-11-25 MX MXPA04004981A patent/MXPA04004981A/es not_active Application Discontinuation
- 2002-11-25 KR KR1020047008311A patent/KR100586131B1/ko not_active Expired - Fee Related
- 2002-11-25 CN CNB028239695A patent/CN1321115C/zh not_active Expired - Fee Related
- 2002-11-25 RU RU2004120063/04A patent/RU2004120063A/ru not_active Application Discontinuation
- 2002-11-25 ES ES02787795T patent/ES2290346T3/es not_active Expired - Lifetime
- 2002-11-25 BR BR0214582-0A patent/BR0214582A/pt not_active IP Right Cessation
- 2002-11-25 PL PL02370746A patent/PL370746A1/xx not_active Application Discontinuation
- 2002-11-25 AU AU2002352122A patent/AU2002352122A1/en not_active Abandoned
- 2002-11-25 AT AT02787795T patent/ATE367160T1/de not_active IP Right Cessation
- 2002-11-25 EP EP02787795A patent/EP1453514B1/en not_active Expired - Lifetime
- 2002-11-25 DE DE60221275T patent/DE60221275T2/de not_active Expired - Fee Related
- 2002-11-25 CA CA002467966A patent/CA2467966A1/en not_active Abandoned
- 2002-11-25 WO PCT/EP2002/013217 patent/WO2003045393A1/en not_active Ceased
- 2002-11-25 JP JP2003546895A patent/JP2005516903A/ja active Pending
- 2002-11-28 AR ARP020104582A patent/AR037459A1/es not_active Application Discontinuation
- 2002-11-29 US US10/307,159 patent/US6906073B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003045393A1 (en) | 2003-06-05 |
| CN1599611A (zh) | 2005-03-23 |
| CN1321115C (zh) | 2007-06-13 |
| CA2467966A1 (en) | 2003-06-05 |
| US20030176441A1 (en) | 2003-09-18 |
| DE60221275T2 (de) | 2008-05-08 |
| RU2004120063A (ru) | 2005-06-10 |
| ATE367160T1 (de) | 2007-08-15 |
| KR20040065570A (ko) | 2004-07-22 |
| US6906073B2 (en) | 2005-06-14 |
| AR037459A1 (es) | 2004-11-10 |
| MXPA04004981A (es) | 2004-08-11 |
| KR100586131B1 (ko) | 2006-06-07 |
| BR0214582A (pt) | 2004-11-03 |
| JP2005516903A (ja) | 2005-06-09 |
| AU2002352122A1 (en) | 2003-06-10 |
| DE60221275D1 (de) | 2007-08-30 |
| EP1453514A1 (en) | 2004-09-08 |
| EP1453514B1 (en) | 2007-07-18 |
| ES2290346T3 (es) | 2008-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0302719A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
| HUE039348T2 (hu) | A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra | |
| PL367058A1 (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
| EG24136A (en) | Piperazine derivatives useful as ccr5 antagonists | |
| PL362900A1 (en) | Piperazine derivatives as 5-ht1b antagonists | |
| PL370746A1 (en) | Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma | |
| AU2003269364A1 (en) | Use of piperazine derivatives as ccr1 antagonists | |
| IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
| IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
| IL169336A0 (en) | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
| AU2002352476A8 (en) | Urea derivatives and their use as vanilloid receptor antagonists | |
| AU2003290059A8 (en) | Use of cd137 antagonists for the treatment of tumors | |
| PL369822A1 (en) | Use of endothelin receptor antagonists in the treatment of tumour diseases | |
| IL198759A (en) | Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety | |
| IL181191A0 (en) | Piperazine and piperidine derivatives and their use as chemokine receptor antagonists | |
| IL150290A0 (en) | The use of mirtazapine for the treatment of sleep disorders | |
| PL375564A1 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
| PL370221A1 (en) | 2-oxazolamines and their use as 5-ht2b receptor antagonists | |
| IL169337A0 (en) | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | |
| AU2003245995A8 (en) | Use of gaba-c receptor antagonists for the treatment of myopia | |
| PL374077A1 (en) | Use of 5-ht2 receptor antagonists for the treatment of sleep disorders | |
| SI1379239T1 (sl) | N-(2-ariletil)benzilamini, uporabljeni kot antagonisti receptorja 5-ht6 | |
| IL162125A0 (en) | Use of n-(indolcarbonyl-) piperazine derivatives | |
| AU2003241051A8 (en) | Use of shp-1 for the therapy of asthma | |
| AU2002363582A1 (en) | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |